Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Dec 5. doi: 10.1007/s40262-019-00852-3. [Epub ahead of print] No abstract available.

PMID:
31802402
2.

Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Dec 5. doi: 10.1007/s40262-019-00848-z. [Epub ahead of print] No abstract available.

PMID:
31802401
3.

Authors' Reply to Nicolas: "Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Dec 5. doi: 10.1007/s40262-019-00851-4. [Epub ahead of print] No abstract available.

PMID:
31802398
4.

[Assessment for antihypertensive drug intake in France in 2019 and adherence].

Bouhanick B, Vaïsse B, Schavgoulidze A, Gandia P.

Presse Med. 2019 Dec;48(12):1520-1526. doi: 10.1016/j.lpm.2019.08.009. Epub 2019 Nov 21. Review. French.

PMID:
31761608
5.

Suicide Attempts: How Does the Acute Use of Alcohol Affect Suicide Intent?

Salles J, Tiret B, Gallini A, Gandia P, Arbus C, Mathur A, Bougon E.

Suicide Life Threat Behav. 2019 Sep 18. doi: 10.1111/sltb.12586. [Epub ahead of print]

PMID:
31532854
6.

Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach.

Willeman T, Tonini J, Garnaud C, Bailly S, Gandia P, Stanke-Labesque F, Maubon D, Gautier-Veyret E.

Fundam Clin Pharmacol. 2019 Sep 10. doi: 10.1111/fcp.12507. [Epub ahead of print]

PMID:
31505058
7.

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Oct;58(10):1353-1354. doi: 10.1007/s40262-019-00815-8. No abstract available.

8.

Memory impairment following intentional self-poisoning with benzodiazepines: Should we pay more attention to attention?

Salles J, Pariente J, Schmitt L, Lauque D, Lanot T, Very E, Gandia P, Lemesle B, Arbus C, Giron A.

J Psychopharmacol. 2019 Nov;33(11):1428-1435. doi: 10.1177/0269881119867609. Epub 2019 Aug 21.

PMID:
31432730
9.

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 21. doi: 10.1007/s40262-019-00812-x. [Epub ahead of print]

PMID:
31432471
10.

Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.

Baklouti S, Massip C, Mane C, Guet-Revillet H, Murris M, Concordet D, Gandia P.

J Antimicrob Chemother. 2019 Oct 1;74(10):3122-3123. doi: 10.1093/jac/dkz307. No abstract available.

PMID:
31335940
11.

[Assessment for antihypertensive drug intake: How, where and when?]

Bouhanick B, Fonquernie P, Bedue I, Schavgoulidze A, Gandia P.

Therapie. 2019 Dec;74(6):651-664. doi: 10.1016/j.therap.2019.05.002. Epub 2019 May 28. French.

PMID:
31301815
12.

Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9. No abstract available.

PMID:
31187472
13.

Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w. No abstract available.

14.

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):961-963. doi: 10.1007/s40262-019-00781-1. No abstract available.

15.

Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):967-968. doi: 10.1007/s40262-019-00780-2. No abstract available.

16.

Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3.

17.

Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR).

Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Goutelle S, Lefeuvre S, Mongardon N, Roger C, Scala-Bertola J, Lemaitre F, Garnier M.

Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9. Review.

18.

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy.

Guerveno C, Raymond S, Metsu D, Gandia P, Izopet J, Martin-Blondel G, Delobel P.

AIDS. 2019 Mar 1;33(3):593-594. doi: 10.1097/QAD.0000000000002089. No abstract available.

PMID:
30702524
19.

Isavuconazole Kinetic Exploration for Clinical Practice.

Darnaud L, Lamoureux F, Godet C, Pontier S, Debard A, Venisse N, Martins P, Concordet D, Gandia P.

Drugs R D. 2018 Dec;18(4):317-321. doi: 10.1007/s40268-018-0251-y.

20.

Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.

Oumar AA, Bagayoko-Maiga K, Bahachimi A, Maiga M, Cere MC, Diarra Z, Chatelut E, Sylla M, Murphy RL, Dao S, Gandia P.

J Pharmacol Exp Ther. 2018 Sep;366(3):479-484. doi: 10.1124/jpet.118.249938. Epub 2018 Jul 9.

PMID:
29986950
21.

Determination of dolutegravir's unbound fraction in human plasma using validated equilibrium dialysis and LC-MS/MS methods.

Metsu D, Lanot T, Fraissinet F, Picot M, Concordet D, Cabrol M, Dubois-Galopin F, Chatelut E, Delobel P, Gandia P.

Clin Chim Acta. 2018 Apr;479:56-65. doi: 10.1016/j.cca.2017.12.034. Epub 2017 Dec 22.

PMID:
29277535
22.

Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria.

Milián L, Peris JE, Gandía P, Andújar I, Pallardó L, Górriz JL, Blas-García A.

AIDS. 2017 Jul 31;31(12):1679-1684. doi: 10.1097/QAD.0000000000001572.

PMID:
28650379
23.

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

Metsu D, Toutain PL, Chatelut E, Delobel P, Gandia P.

J Antimicrob Chemother. 2017 Sep 1;72(9):2407-2409. doi: 10.1093/jac/dkx176.

PMID:
28595364
24.

Patient emergency assessment following deliberate self-poisoning with benzodiazepines: Can cognitive markers predict recall of the psychiatric interview? A pilot study.

Salles J, Pariente J, Dimeglio C, Gandia P, Lemesle B, Giron A, Franchitto N, Schmitt L, Very E.

J Psychopharmacol. 2017 Oct;31(10):1362-1368. doi: 10.1177/0269881117705088. Epub 2017 Apr 26.

PMID:
28441901
25.

Pharmacokinetics of Teicoplanin in a Breastfeeding Mother.

Fraissinet F, Lesourd M, Naudoux N, Metsu D, Gandia P.

Breastfeed Med. 2017 May;12:244-246. doi: 10.1089/bfm.2017.0016. Epub 2017 Mar 17. No abstract available.

PMID:
28304183
26.

Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma.

Gandia P, Jaudet C, Everaert H, Heemskerk J, Vanbinst AM, de Mey J, Duerinck J, Neyns B, de Ridder M, Chatelut E, Concordet D.

Clin Pharmacokinet. 2017 Aug;56(8):953-961. doi: 10.1007/s40262-016-0490-4.

PMID:
27995528
27.

Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?

Metsu D, Seraissol P, Delobel P, Cinq-Frais C, Cuzin L, Izopet J, Chatelut E, Gandia P.

Fundam Clin Pharmacol. 2017 Apr;31(2):245-253. doi: 10.1111/fcp.12245. Epub 2016 Oct 25.

PMID:
27664801
28.

Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome.

Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1777-1782. doi: 10.2215/CJN.00320116. Epub 2016 Jul 21.

29.

Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?

Gandia P, Jaudet C, Chatelut E, Concordet D.

Clin Pharmacokinet. 2017 Feb;56(2):101-106. doi: 10.1007/s40262-016-0437-9.

PMID:
27395047
30.

Quinine unbound concentration is the best marker for therapeutic drug monitoring.

de Pablos-Martinez C, Porte L, Fraissinet F, Berry A, Séraissol P, Lavit M, Chatelut E, Concordet D, Gandia P.

Therapie. 2016 Oct;71(5):487-489. doi: 10.1016/j.therap.2016.02.032. Epub 2016 Apr 11.

PMID:
27203159
31.

Quinine Unbound Concentration Has to Be Used for Therapeutic Drug Monitoring.

de Pablos-Martinez C, Porte L, Fraissinet F, Berry A, Séraissol P, Lavit M, Chatelut E, Concordet D, Gandia P.

Ther Drug Monit. 2016 Aug;38(4):556-7. doi: 10.1097/FTD.0000000000000304. No abstract available.

PMID:
27019100
32.

A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation.

Pouché L, Koitka M, Stojanova J, Woillard JB, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle JP, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen BS, Marquet P, Picard N.

Pharmacogenomics. 2016 Mar;17(4):375-91. doi: 10.2217/pgs.15.181. Epub 2016 Feb 19.

PMID:
26894651
33.

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

Melis V, Usach I, Gandía P, Peris JE.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1022-8. doi: 10.1128/AAC.02129-15. Print 2016 Feb.

34.

[Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].

Negri L, Le Grusse J, Séraissol P, Lavit M, Houin G, Gandia P.

Therapie. 2014 Nov-Dec;69(6):509-16. doi: 10.2515/therapie/2014202. Epub 2014 Oct 16. French.

PMID:
25314930
35.

Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline.

Usach I, Melis V, Gandía P, Peris JE.

Antimicrob Agents Chemother. 2014 Dec;58(12):7041-8. doi: 10.1128/AAC.03312-14. Epub 2014 Sep 15.

36.

Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment.

Florent A, Gandia P, Seraissol P, Chatelut E, Houin G.

Ther Drug Monit. 2014 Dec;36(6):752-8. doi: 10.1097/FTD.0000000000000095.

PMID:
24819971
37.

Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.

Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N.

Ann Transplant. 2014 Feb 10;19:76-81. doi: 10.12659/AOT.889691.

38.

Long-term prospective population PK study in GIST patients--letter.

Chatelut E, Gandia P, Gotta V, Widmer N.

Clin Cancer Res. 2013 Feb 15;19(4):949. doi: 10.1158/1078-0432.CCR-12-3445. Epub 2013 Feb 5. No abstract available.

39.

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?

Gandia P, Arellano C, Lafont T, Huguet F, Malard L, Chatelut E.

Cancer Chemother Pharmacol. 2013 Feb;71(2):531-6. doi: 10.1007/s00280-012-2035-3. Epub 2012 Nov 27.

PMID:
23183914
40.

Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.

Arellano C, Gandia P, Lafont T, Jongejan R, Chatelut E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:94-100. doi: 10.1016/j.jchromb.2012.09.007. Epub 2012 Sep 7.

PMID:
23000741
41.

Circuitous diagnosis in concealed self-poisoning with Nerium oleander.

Vallé B, Lairez O, Gandia P, Rouge D, Franchitto N.

Clin Toxicol (Phila). 2012 Mar;50(3):228-9. doi: 10.3109/15563650.2011.653569. Epub 2012 Feb 16. No abstract available.

PMID:
22335506
42.

Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer.

Gandia P, Arellano C, Chalret du Rieu Q, Lochon I, Campone M, Pierga JY, Poublanc M, Hennebelle I, Filleron T, Chatelut E, Delord JP.

Curr Clin Pharmacol. 2011 Nov;6(4):274-9.

PMID:
22082325
43.

Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.

Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F, Bessenay L, Libert F, Harambat J, Bouchet S, Broux F, Compagnon P, Marquet P.

Pharmacol Res. 2011 May;63(5):423-31. doi: 10.1016/j.phrs.2011.01.009. Epub 2011 Jan 25.

PMID:
21272643
44.

Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships.

Prémaud A, Rousseau A, Johnson G, Canivet C, Gandia P, Muscari F, Peron JM, Rostaing L, Marquet P, Kamar N.

Pharmacol Res. 2011 May;63(5):432-8. doi: 10.1016/j.phrs.2011.01.005. Epub 2011 Jan 15.

PMID:
21241803
45.

In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete.

Ahmad G, Moinard N, Jouanolou V, Daudin M, Gandia P, Bujan L.

Toxicol In Vitro. 2011 Mar;25(2):485-91. doi: 10.1016/j.tiv.2010.11.020. Epub 2010 Dec 2.

PMID:
21130153
46.

Influence of pre-analytical conditions on plasma ribavirin concentrations.

Gandia P, Trancart S, Nicot F, Barange K, Alric L, Izopet J, Séraissol P, Lavit M, Houin G.

Arzneimittelforschung. 2010;60(10):636-9. doi: 10.1055/s-0031-1296338.

PMID:
21125815
47.

The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine.

Bonnefille P, Sezgin-Bayindir Z, Belkhelfa H, Arellano C, Gandia P, Woodley J, Houin G.

Fundam Clin Pharmacol. 2011 Feb;25(1):104-14. doi: 10.1111/j.1472-8206.2010.00904.x. Epub 2010 Dec 1.

PMID:
21121944
48.

Modification of aflatoxin B1 and ochratoxin A toxicokinetics in rats administered a yeast cell wall preparation.

Firmin S, Gandia P, Morgavi DP, Houin G, Jouany JP, Bertin G, Boudra H.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010 Aug;27(8):1153-60. doi: 10.1080/19440041003801174.

PMID:
20512710
49.

Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs.

Arellano C, Gandia P, Bettuing L, Woodley J, Chatelut E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 1;878(7-8):645-52. doi: 10.1016/j.jchromb.2010.01.019. Epub 2010 Jan 25.

PMID:
20138015
50.

[Immediate and delayed hypersensitivity reactions to iodinated radiographic contrast agents: an update].

Khachman D, Gandia P, Sallerin F, Mailly N.

Therapie. 2009 Sep-Oct;64(5):331-9. doi: 10.2515/therapie/2009040. Epub 2009 Oct 30. Review. French.

PMID:
19863909

Supplemental Content

Loading ...
Support Center